GEP-NET radiomics: a systematic review and radiomics quality score assessment.
Objective: The number of radiomics studies in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is rapidly increasing. This systematic review aims to provide an overview of the available evidence of radiomics for clinical outcome measures in GEP-NETs, to understand which applications hold the...
| Publicado en: | European Radiology Vol. 32; no. 10; pp. 7278 - 7295 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | research systematic review Journal Article |
| Publicado: |
Springer Nature
Oct2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=159104005&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 159104005 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09387994 NPH jtl: European Radiology issn: 09387994 maglogo: N pubinfo: dt: Oct2022 vid: 32 iid: 10 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 159104005 158180313 159104005 NLM35882634 159104005 10.1007/s00330-022-08996-w NLM35882634 159104005 ppf: 7278 ppct: 17 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: GEP-NET radiomics: a systematic review and radiomics quality score assessment. aug: au: Staal, Femke C. R. Aalbersberg, Else A. van der Velden, Daphne Wilthagen, Erica A. Tesselaar, Margot E. T. Beets-Tan, Regina G. H. Maas, Monique affil: Department of Radiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands sug: subj: Pancreatic Neoplasms Pathology Neuroendocrine Tumors Pathology Intestinal Neoplasms Intestinal Neoplasms Pathology Stomach Neoplasms Pathology Human ab: Objective: The number of radiomics studies in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is rapidly increasing. This systematic review aims to provide an overview of the available evidence of radiomics for clinical outcome measures in GEP-NETs, to understand which applications hold the most promise and which areas lack evidence.Methods: PubMed, Embase, and Wiley/Cochrane Library databases were searched and a forward and backward reference check of the identified studies was executed. Inclusion criteria were (1) patients with GEP-NETs and (2) radiomics analysis on CT, MRI or PET. Two reviewers independently agreed on eligibility and assessed methodological quality with the radiomics quality score (RQS) and extracted outcome data.Results: In total, 1364 unique studies were identified and 45 were included for analysis. Most studies focused on GEP-NET grade and differential diagnosis of GEP-NETs from other neoplasms, while only a minority analysed treatment response or long-term outcomes. Several studies were able to predict tumour grade or to differentiate GEP-NETs from other lesions with a good performance (AUCs 0.74-0.96 and AUCs 0.80-0.99, respectively). Only one study developed a model to predict recurrence in pancreas NETs (AUC 0.77). The included studies reached a mean RQS of 18%.Conclusion: Although radiomics for GEP-NETs is still a relatively new area, some promising models have been developed. Future research should focus on developing robust models for clinically relevant aims such as prediction of response or long-term outcome in GEP-NET, since evidence for these aims is still scarce.Key Points: • The majority of radiomics studies in gastroenteropancreatic neuroendocrine tumours is of low quality. • Most evidence for radiomics is available for the identification of tumour grade or differentiation of gastroenteropancreatic neuroendocrine tumours from other neoplasms. • Radiomics for the prediction of response or long-term outcome in gastroenteropancreatic neuroendocrine tumours warrants further research. pubtype: Academic Journal doctype: research systematic review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|